Association Between the IL-6 rs1800795 Polymorphism and the Risk of Cervical Cancer: A Meta-Analysis of 1210 Cases and 1525 Controls

Li, Haiping; Lyu, Dan; Yan, Zhang; Sheng, Lianbing

doi:10.1177/1533034616672806

Cited by 20 publications

(34 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several recent meta-analysis have focused on the association between IL-6 promoter polymorphisms and cancer risk. Two meta-analysis showed that rs1800795 polymorphism increased the risk of prostate cancer and cervical cancer [ 108 , 109 ]. Though, the result same with ours, it still exist some problems.…”

Section: Discussionmentioning

confidence: 99%

Genetic polymorphisms of IL-6 promoter in cancer susceptibility and prognosis: a meta-analysis

et al. 2018

View full text Add to dashboard Cite

IL-6 is critical for tumorigenesis. However, previous studies on the association of IL-6 promoter polymorphisms with predisposition to different cancer types are somewhat contradictory. Therefore, we performed this meta-analysis regarding the relationship between IL-6 promoter single nucleotide polymorphisms and cancer susceptibility and prognosis. Up to April 2017, 97 original publications were identified covering three IL-6 promoter SNPs. Our results showed statistically significant association between IL-6 promoter and cancer risk and prognosis. Subgroup analysis indicated that rs1800795 was significantly associated with increased risk of cervical cancer, colorectal cancer, breast cancer, prostate cancer, lung cancer, glioma, non-Hodgkin’s lymphoma and Hodgkin’s lymphoma but not gastric cancer and multiple myeloma. Furthermore, rs1800796 was significantly associated with increased risk of lung cancer, prostate cancer and colorectal cancer but not gastric cancer. Additionally, rs1800797 was significantly association with breast cancer, non-Hodgkin’s lymphoma, B-cell lymphoma and diffuse large B-cell lymphoma but not gastric cancer. Simultaneously, rs1800795 and rs1800796 were associated with a significantly higher risk of cancer in Asia and Caucasian, rs1800797 was associated with a significantly risk of cancer in Caucasian but not in Asia. Furthermore, IL-6 promoter polymorphisms were significantly associated with the prognosis of cancer. Considering these promising results, IL-6 promoter including rs1800795, rs1800796 and rs1800797 may be a tumor marker for cancer therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Genetic polymorphisms of IL-6 promoter in cancer susceptibility and prognosis: a meta-analysis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…A recent study by Pu et al [ 26 ] found that cervical cancer risks were significantly higher in carriers of C allele of rs1800795 polymorphism than those with GG genotype. By now, only one meta-analysis by Liu et al [ 30 ] was conducted to explore the association between IL-6 -174G>C and cervical cancer risk. This meta-analysis was updated to July 2015 with five publications included (1210 cases and 1525 controls).…”

Section: Discussionmentioning

confidence: 99%

Association of IL-6 -174G>C (rs1800795) polymorphism with cervical cancer susceptibility

Duan

Chen²,

Shi

et al. 2018

Bioscience Reports

View full text Add to dashboard Cite

Interleukin-6 (IL-6) is a multifunctional cytokine that has been implicated in the etiology of cancer. Several case–control studies have been conducted to assess the association of IL-6 -174G>C (rs1800795) polymorphism with the risk of cervical cancer, yet with conflicting conclusions. To derive a more precise estimation of the relationship, we performed this meta-analysis updated to June 2018. A total of seven original publications were identified covering IL-6 -174G>C (rs1800795) polymorphism. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the relationship strengths. Statistically significant relationship was observed between IL-6 -174G>C polymorphism and cervical cancer risk (OR = 0.61, 95% CI: 0.40–0.94 for GG vs. CC, and OR = 0.77, 95% CI: 0.64–0.93 for G vs. C). Moreover, the significant association was found among Asians (OR = 0.46, 95% CI: 0.29–0.75 for GG vs. CC, and OR = 0.70, 95% CI: 0.57–0.89 for G vs. C); hospital-based subgroup (OR = 0.53, 95% CI: 0.38–0.72 for GG vs. CC, and OR = 0.73, 95% CI: 0.61–0.87 for G vs. C); and Hardy–Weinberg equilibrium ≤0.05 (OR = 0.56, 95% CI: 0.37–0.86 for GG vs. GC, and OR = 0.66, 95% CI: 0.47–0.93 for G vs. C). This meta-analysis showed the evidence that the IL-6 -174G>C polymorphism was a low-penetrance susceptibility variant for cervical cancer. Further large-scale case–control studies are needed to confirm these results.

show abstract

“…Some epidemiological studies suggested that IL-12B rs3212227 and IL-6 rs1800795 polymorphisms are associated with an increased risk of cervical cancer. However, two recent meta-analyses were performed to evaluate IL-12B rs3212227 and IL-6 rs1800795 polymorphisms with cervical cancer risk and their results indicated that no significant association was found among all ethnicities (Chang et al, 2015;Liu et al, 2017;Pu et al, 2016;Zheng et al, 2017). Therefore, controversy and inconformity still remained about IL-12B rs3212227 and IL-6 rs1800795 polymorphisms and most of studies recruited a limited sample capacity, which is insufficient to get a firm conclusion about the associations of these polymorphisms with development of cervical cancer.…”

Section: Association Of Il-12b Rs3212227 and Il-6 Rs1800795mentioning

confidence: 99%

Association of IL-12B rs3212227 and IL-6 rs1800795 Polymorphisms with Susceptibility to Cervical Cancer: A Systematic Review and Meta-Analysis

Karimi-Zarchi¹,

Abbasi²,

Javaheri³

et al. 2020

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Cervical cancer is the second most commonly diagnosed malignancy and third leading cause of cancer-related mortality among women in less developed countries (Karimi Zarchi et al., 2010; Mousavi et al., 2008). According to GLOBOCAN, cervical cancer accounts for 528,000 new cases and 266,000 deaths worldwide in 2012 (Parkin et al., 2005). Although, it has been widely accepted for several decades that Human papillomavirus (HPV) is the main risk factor for development of cervical cancer (Behtash et al., 2009; Farbod et al., 2019; Ghaemmaghami et al., 2008), HPV infections have developed to persistent infection in only a very few cases and it is sufficient to induce cervical cancer in an even smaller proportion

show abstract

Association Between the IL-6 rs1800795 Polymorphism and the Risk of Cervical Cancer: A Meta-Analysis of 1210 Cases and 1525 Controls

Cited by 20 publications

References 16 publications

Genetic polymorphisms of IL-6 promoter in cancer susceptibility and prognosis: a meta-analysis

Genetic polymorphisms of IL-6 promoter in cancer susceptibility and prognosis: a meta-analysis

Association of IL-6 -174G>C (rs1800795) polymorphism with cervical cancer susceptibility

Association of IL-12B rs3212227 and IL-6 rs1800795 Polymorphisms with Susceptibility to Cervical Cancer: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About

Association Between the IL-6 rs1800795 Polymorphism and the Risk of Cervical Cancer: A Meta-Analysis of 1210 Cases and 1525 Controls

Cited by 20 publications

References 16 publications

Genetic polymorphisms of IL-6 promoter in cancer susceptibility and prognosis: a meta-analysis

Genetic polymorphisms of IL-6 promoter in cancer susceptibility and prognosis: a meta-analysis

Association of IL-6 -174G&gt;C (rs1800795) polymorphism with cervical cancer susceptibility

Association of IL-12B rs3212227 and IL-6 rs1800795 Polymorphisms with Susceptibility to Cervical Cancer: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About

Association of IL-6 -174G>C (rs1800795) polymorphism with cervical cancer susceptibility